Emerging treatment options for acute lymphoblastic leukemia: Focus on CAR T-cell therapy

Patrick A Brown, Bijal Shah

Research output: Contribution to journalArticle

Abstract

Acute lymphoblastic leukemia (ALL) comprises a heterogeneous group of diseases with different morphologic, cytogenetic, and molecular subgroups, some of which have significant therapeutic implications. It typically presents with an aggressive clinical course, and among adults, responds poorly to standard chemotherapy, and carries a high risk for relapse. Despite the significant progress made in inducing remission, frequent relapses remain a challenge. Novel drugs, such as potent later-generation tyrosine kinase inhibitors, antibody-drug conjugates, bispecific monoclonal antibodies, and chimeric antigen receptor (CAR) T-cell therapies, are being investigated in patients with ALL. This summary describes therapies currently approved for the treatment of patients with ALL, identifies emerging targeted immunotherapies for patients with ALL, and discusses adverse events and mechanisms of resistance.

Original languageEnglish (US)
Pages (from-to)651-655
Number of pages5
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume16
Issue number5S
DOIs
Publication statusPublished - May 1 2018

    Fingerprint

ASJC Scopus subject areas

  • Oncology

Cite this